The Beat Smarter Diagnostics: Dr. Julie Schulz on Turning Lab Testing into a Strategic Advantage for Value-Based Care
About Dr. Julie Schulz:
Dr. Julie Schulz, MD, MPH, is a physician executive and product leader based in Los Angeles with a proven track record of driving innovation at the intersection of healthcare, technology, and business. Over the past 15 years, she has built and led teams developing healthcare decision support, analytics, and consumer health products across value-based care, women’s health, and life sciences. As VP of Product at Avalon Healthcare Solutions, she leads strategy for next-generation diagnostics platforms. Previously, at HALO Diagnostics and Doctor Evidence, she guided product and business development efforts that integrated imaging, laboratory, and evidence-based analytics to improve patient and physician experiences. Earlier roles at Lumere and Sg2 honed her expertise in clinical data, product-market fit, and scaling evidence-driven solutions. Published in leading journals, Dr. Schulz combines deep clinical insight with strategic leadership to advance innovations that improve healthcare outcomes and drive measurable business impact.
Things You’ll Learn:
- Diagnostic intelligence can transform diagnostics from a cost center into a strategic asset that improves quality and lowers costs.
- Physicians face overwhelming volumes of new tests and guidelines, and AI-powered decision support can ease their cognitive burden.
- By removing prior authorization barriers, patients can transition from diagnosis to treatment in just 15 days, rather than the typical 60 days.
- Data shows that healthier patients are more likely to receive GLP-1 prescriptions, revealing a need for better risk-adjusted care strategies.
- True innovation in healthcare depends on communication, simplifying complexity and aligning clinicians, payers, and technologists toward shared goals.
Resources: